PIA
GNMK

Piedmont Investment Advisors’s GenMark Diagnostics, Inc GNMK Stock Holding History

Piedmont Investment Advisors’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-900
Closed -$6K – 2666
2018
Q2 		$6K Buy
+900
New +$5.95K ﹤0.01% 2070

Other funds holding GNMK

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Piedmont Investment Advisors's GNMK Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2018, closing a stake of 900 shares — an estimated $6K sold.

Piedmont Investment Advisors first reported a position in GNMK in Q2 2018 and held it in 1 quarter. The position peaked at $6K in Q2 2018. 106 funds tracked by Wall St. Rank hold GNMK as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining GenMark Diagnostics, Inc position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 900 GenMark Diagnostics, Inc shares in Q3 2018, an estimated $6K.
  • Piedmont Investment Advisors first reported a position in GenMark Diagnostics, Inc in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's GenMark Diagnostics, Inc position peaked at $6K in Q2 2018.
  • 106 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.